NCT00795444View on ClinicalTrials.gov

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

HIV-1

Interventions

DRUG

maraviroc

Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.

Trial Locations (1)

28034

Hospital Universitario Ramon Y Cajal, Madrid

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

NCT00795444 - Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 | Biotech Hunter | Biotech Hunter